Effect Of Katankateryadi Kwatha And Shuddha Shilajit In The Management Of Type 2 Diabetes Mellitus

A Comparative Clinical Study To Evaluate The Efficacy Of Katankateryadi Kwatha And Shuddha Shilajit In The Management Of Madhumeha W.S.R To Diabetes Mellitus(type 2) - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070254

Enrollment

Registered

2024-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex aged between 30 to 65 years. If yes in any two of the four: 2.Blood sugar –fasting 7.0 – 8.4 mmol/L or ( 125-150mg/dl) PP – 11.0 – 13.8 mmol/l or( 199-250 mg/dl.) Glycosylated Hemoglobin (HbA1c) 6.4% - 7.5% Subjects having classical symptoms of diabetes with random glucose levels =200mg/dl (=250mg/dl) 3.Subjects who are able to come for follow up on fixed visits and are well aware about the treatment plan.(only type 2 DM patients) 4.Subjects willing to participate and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patient suffering from the complications of Diabetes Mellitus like diabetic neuropathy, diabetic retinopathy etc. which require an urgent treatment. 2.patients on any other AYUSH medication for glucose control. Uncontrolled hypertensive subjects(BP with or without medication 140/90 mmHg after 5 min. of rest) 3.patients having any antidiabetic medicine of any other pathy in the last 3 months. 4.patients with any Heart disease or known cases of MI, unstable angina or CHF. 5.patients with current or past diagnosis of malignancy (any malignancy diagnosis in last five years) 6.patients who have a recent history or who are currently known to abuse of alcohol or drugs. 7.patients suffering from major systemic illness necessitating long term drug treatment (rheumatoid arthritis, psycho-neuro-endocrinal disorders,TB, AIDS etc). 8.patients who have completed participation in any other clinical trail during the past six (06 months).

Design outcomes

Primary

Measure	Time frame
Primary Outcomes Would Be Measure By Diabetic Specific Biomarker HbA1C LevelsTimepoint: Day1,Day91	—

Secondary

Measure	Time frame
1.To compare the clinical effect of katankateryadi kwatha and shudder shilajit in the management madhumeha. 2.For assessment of safety and effect of drug that can be helpful for the Diabetic community to combat the ailment.Timepoint: DAY 1, DAY 91	—

Countries

India

Contacts

Public ContactDr Sujata Yadav

Ayurvedic And Unani Tibbia College And Hospital

sujatakcdelhi@gmail.com9810571653

Outcome results